

DIASORIN LAUNCHES THE TWO FASTEST MOLECULAR DIAGNOSTIC TESTS IN THE WORLD TO DETECT FULMINANT LEUKEMIAS

EARLY IDENTIFICATION OF THE DISEASE WILL ALLOW TO TREAT PATIENTS WITH SPECIFIC AND EXTREMELY EFFECTIVE THERAPIES

September 9th, 2015 - Saluggia (VC) - **DiaSorin** (FTSE Mid Cap: DIA) launches 2 new molecular diagnostic tests, **lam PML-RARA Detection bcr1,3** and **lam PML-RARA Discrimination bcr2**, available on the market outside the US, for the identification of the **genetic cause of Acute Promyelocytic Leukemia**.

When used together, the new tests allow reliable, complete and extremely fast (15 minutes instead of 4 hours) **detection of the PML-RARA translocation**, which is the genetic cause of “**Fulminant Leukemia**”, technically called Acute Promyelocytic Leukemia, which is considered the most aggressive type of blood cancer that, if not identified in time, is fatal.

The timing of DiaSorin tests will allow medical staff to treat the patient immediately with effective therapies, ensuring the patient's care and surviving in more than 90% of cases.

Paul Eros, Global Vice President of Marketing Molecular in DiaSorin, commented: *“After the launch, at the end of 2014, of the first test for the diagnosis of chronic myeloid leukemia and Ph + acute lymphoblastic leukemia, DiaSorin today marks another important milestone within onco-haematology. The two new tests based on our innovative proprietary Q-LAMP technology are the only solution available on the market for ultra-rapid molecular diagnosis of Acute Promyelocytic Leukemia. In just 15 minutes, from today, you can save an extra life”*.

Carlo Rosa, CEO of DiaSorin Group, commented: *“I am proud of our new successful launch in the field of onco-haematology that demonstrates once again our commitment to innovative molecular diagnostics research. Acute Promyelocytic Leukemia represents the urgency “par excellence” where time to results can make the difference between life and death and where DiaSorin offers the fastest solution on the market”*.



The Diagnostic Specialist

Press Release

REFERENCE TABLE FOR DIASORIN PRODUCTS

Assay name	LIAISON IAM PML-RARA Detection bcr1,3 and PML-RARA Discrimination bcr2		
Diagnosis	Qualitative determination of Acute Promyelocytic Leukemia		
Business segment	Immunodiagnostics	Molecular Diagnostics	✓
Technology	CLIA	IXT	
	ELISA	IAM	✓
	RIA		
Clinical Area	Infectious Diseases		
	Hepatitis and Retroviruses		
	Oncology & Endocrinology		
	Bone & Mineral		
	Cardiac Markers		
	GI Stool Testing		
		Infectious Diseases	
		Onco-hematology	✓

About DiaSorin

Headquartered in Italy and listed in the FTSE Mid Cap Index, DiaSorin is a global leader in the In Vitro Diagnostics (IVD) field. For over 40 years, the Company has been developing, producing and marketing reagent kits for IVD worldwide. Through constant investments in research and development, and using its own distinctive expertise in the field of immunodiagnostics to deliver a high level of innovation, DiaSorin offers today the broadest range of specialty tests available in the immunodiagnostics market and new tests in the molecular diagnostics markets, which identify DiaSorin Group as the IVD “diagnostics specialist”.

For additional information, please contact:

Riccardo Fava

Investor Relations & Corporate Communication Director

Tel: +39.0161.487988

riccardo.fava@diasorin.it

Margherita Sacerdoti

Investor Relations Specialist

Tel: +39.0161.487456

margherita.sacerdoti@diasorin.it